FDA guidance on API-excipient co-crystals unnecessary; Amgen
Amgen has called FDA draft guidance on API-excipient co-crystals unnecessary in its written response to the Agency.
News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs